AstraZeneca PLC is acquiring CinCor Pharma, Inc. for $1.3bn upfront in a bid to bolster its cardiorenal pipeline through the addition of a next-generation aldosterone synthase inhibitor (ASI) asset that could pair well with Farxiga. The company announced the deal on the opening day of the J.P. Morgan Healthcare Conference on 9 January.
AstraZeneca Nabs CinCor’s Hypertension Asset In $1.3bn Acquisition
Potential Combination With Farxiga
The UK major is acquiring CinCor in a deal that could be worth up to $1.8bn, in return getting hold of its Phase II hypertension candidate, baxdrostat, which offers combination potential with Farxiga.
More from Deals
More from Business
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
• By
The four-year-old firm said it plans to advance programs toward the clinic from the funding round, which comes just over a year after signing two major pharma partnerships.
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.